MedTrace Logo

Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage

NCT05707585 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2064

Last updated 2023-02-01

No results posted yet for this study

Summary

The goal of this multicenter observational study is to evaluate the lung cancer diagnostic value of epigenetic imprinting detection in bronchoalveolar lavage. This study will mainly focus on varifing the previously identified epigenetic imprinting biomarkers for lung cancer and upgrading and validating a lung cancer imprinting diagnostic model specifically for bronchoalveolar lavage. The lavage sample will be collected from each eligible paticipants under bronchialscopy and undergo QCIGISH detection to analyze the allelic expression status of imprinted genes. The QCIGISH detection results will be compared with the final surgical histopathology. No interventions will be taken according to the QCIGISH detection results.

Conditions

Interventions

DIAGNOSTIC_TEST

Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)

Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Zongda Hospital affiliated to Southeast University

    collaborator NETWORK

  • West China Hospital

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Lisen Imprinting Diagnostics, Inc.

    collaborator UNKNOWN

  • The Second Affiliated Hospital of Dalian Medical University

    lead OTHER

Principal Investigators

  • Qi Wang, MD · The Second Affiliated Hospital of Dalian Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-29
Primary Completion
2024-01-15
Completion
2024-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05707585 on ClinicalTrials.gov